Recent developments in oral lipid-based drug delivery

Journal of Drug Delivery Science and Technology

Volumn 23, Issue 4, 2013, Pages 375-382

  Thomas, N ^a   Rades, T ^a   Mullertz A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

(Super )SNEDDS; Absorption; In vitro lipolysis; Lipids

Indexed keywords

2 MONOACYLGLYCERIDE; ALBENDAZOLE; ALFACALCIDOL; ALPHA TOCOPHEROL; AMPRENAVIR; CINNARIZINE; CIPROFLOXACIN; CLOMETHIAZOLE; CYCLOSPORIN A; DANAZOL; DIACYLGLYCEROL; DRONABINOL; FENOFIBRATE; HALOFANTRINE; LIPID; LOPINAVIR PLUS RITONAVIR; MACROGOL; OLEIC ACID; PHOSPHATIDYLCHOLINE; PROBUCOL; PROPYLENE GLYCOL; RITONAVIR; SAQUINAVIR; SEOCALCITOL; SESAME SEED OIL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG SOLUBILITY; IN VITRO STUDY; LIPOLYSIS; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PH; REVIEW; ULTRACENTRIFUGATION;

EID: 84881568861     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(13)50054-2     Document Type: Review

References (94)

1. Gursoy R. N., Benita S. - Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. - Biomed. Pharmacother., 58, 173-182, 2004. (Pubitemid 38479922)
2. Babu N. J., Nangia A. - Solubility advantage of amorphous drugs and pharmaceutical cocrystals. - Cryst. Growth Des., 11, 2662-2679, 2011.
3. Hauss D. H. Ed. - Oral lipid-based formulations: Enhancing the bioavailability of poorly water-soluble drugs. - Informa Healthcare, New York, 2007.
4. Kuentz M. - Lipid-based formulations for oral delivery of lipophilic drugs. - Drug Discovery Today: Technologies, 9, e97-e104, 2012.
5. Chakraborty S., Shukla D., Mishra B., Singh S. - Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. - Eur. J. Pharm. Biopharm., 73, 1-70, 2009.
6. Grove M., Müllertz A., Nielsen J. L., Pedersen G. P. - Bioavailability of seocalcitol. II. Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. - Eur. J. Pharm. Sci., 28, 233-242, 2006. (Pubitemid 43766097)
7. Müllertz A., Ogbonna A., Ren S., Rades T. - New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. - J. Pharm. Pharmacol., 62, 1622-1636, 2010.
8. Williams III R. O., Watts A. B., Miller D. A. (Eds.) - Formulating Poorly Water Soluble Drugs. - Springer, New York, 2012.
9. Fahr A., Liu X. - Drug delivery strategies for poorly water-soluble drugs. - Expert Opin. Drug Deliv., 4, 403-416, 2007. (Pubitemid 47249138)
10. Hauss D. H. - Oral lipid-based formulations. - Adv. Drug Delivery. Rev., 59, 667-676, 2007.
11. Porter C. J. H., Trevaskis N. L., Charman W. N. - Lipids and lipidbased formulations: Optimizing the oral delivery of lipophilic drugs. - Nat. Rev. Drug Discovery, 6, 231-248, 2007. (Pubitemid 46344627)
12. Anton N., Vandamme T. - Nano-emulsions and micro-emulsions: Clarifications of the critical differences. - Pharm. Res., 28, 978-985, 2011.
13. Niederquell A., Kuentz M. - Proposal of stability categories for nano-dispersions obtained from pharmaceutical self-emulsifying formulations. - Int. J. Pharm., online first, http://dx.doi.org/10.1016/j.ijpharm.2013.02.005, 2013.
14. Dressman J. B., Amidon G. L., Reppas C., Shah V. P. - Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. - Pharm. Res., 15, 11-22, 1998. (Pubitemid 28080861)
15. Fatouros D. G., Walrand I., Bergenstahl B., Müllertz A. - Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. - Pharm. Res., 26, 361-374, 2008.
16. Carriere F., Barrowman J. A., Verger R., Laugier R. - Secretion and contribution to lipolysis of gastric and pancreatic lipases during atest meal in humans. - Gastroenterology, 105, 876-888, 1993. (Pubitemid 23249500)
17. Golding M., Wooster T. J. - The influence of emulsion structure and stability on lipid digestion. - Curr. Opin. Colloid Interface Sci., 15, 90-101, 2010.
18. Borgstróm B. - Influence of bile salt, pH, and time on the action of pancreatic lipase: Physiological implications. - J. Lipid Res., 5, 522-531, 1964.
19. Borgstróm B., Erlanson-Albertsson C., Wieloch T. - Pancreatic colipase: Chemistry and physiology. - J. Lipid Res., 20, 805-816, 1979. (Pubitemid 10245347)
20. Carey M. C., Small D. M., Bliss C. M. - Lipid digestion and absorption. - Annu. Rev. Physiol., 45, 651-677, 1983.
21. Patton J. S., Carey M. C. - Watching fat digestion. - Science, 204, 145-148, 1979.
22. Armand M., Pasquier B., André M., Borel P., Senft M., Peyrot J., Salducci J., Portugal H., Jaussan V., Lairon D. - Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract. - Am. J. Clin. Nutr., 70, 1096-1106, 1999.
23. Galia E., Nicolaides E., Hórter D., Lóbenberg R., Reppas C., Dressman J. B. - Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. - Pharm. Res., 15, 698-705, 1998. (Pubitemid 28275645)
24. Jantratid E., Janssen N., Reppas C., Dressman J. D. - Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. - Pharm. Res., 25, 1663-1676, 2008.
25. Christensen J., Schultz K., Mollgard B., Kristensen H. G., Müllertz A. - Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium-and long-chain triacylglycerols. - Eur. J. Pharm. Sci., 23, 287-296, 2004. (Pubitemid 39369884)
26. Kaukonen A. M., Boyd B. J., Porter C. J. H., Charman W. N. - Drug solubilization behavior during in w'irodigestion of simple triglyceride lipid solution formulations. - Pharm. Res., 21, 245-253, 2004. (Pubitemid 38221969)
27. Kleberg K., Jacobsen J., Müllertz A. - Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. - J. Pharm. Pharmacol., 62, 1656-1668, 2010.
28. Caliph S. M., Charman W. N., Porter C. J. H. - Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. - J. Pharm. Sci., 89, 1073-1084, 2000.
29. Holm R., Müllertz A., Pedersen G. P., Kristensen H. G. - Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. - Pharm. Res., 18, 1299-1304, 2001. (Pubitemid 32846323)
30. Wasan K. M. - Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. - Drug Dev. Ind. Pharm., 27, 267-276, 2001. (Pubitemid 32531593)
31. Trevaskis N. L., Charman W. N., Porter C. J. H. - Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? - Mol. Pharm., 7, 2297-2309, 2010.
32. Risovic V., Sachs-Barrable C., Boyd M., Wasan K. M. - Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. - Drug Dev. Ind. Pharm., 30, 767-774, 2004. (Pubitemid 39311017)
33. Buyukozturk F., Benneyan J. C., Carrier R. L. - Impactof emulsionbased drug delivery systems on intestinal permeability and drug release kinetics. - J. Controlled Release, 142, 22-30, 2010.
34. Kossena G., Charman W. N., Wilson C., O'Mahony B., Lindsay B., Hempenstall J., Davison C., Crowley P., Porter C. - Low dose lipid formulations: Effects on gastric emptying and biliary secretion. - Pharm. Res., 24, 2084-2096, 2007. (Pubitemid 47493578)
35. Larsen A., Holm R., Pedersen M., Müllertz A. - Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: In vivo bioavailability and dynamic in vitro lipolysis. - Pharm. Res., 25, 2769-2777, 2008.
36. Humberstone A. J., Charman W. N. - Lipid-based vehicles for the oral delivery of poorly water soluble drugs. - Adv. Drug Delivery. Rev., 25, 103-128, 1997.
37. de Smidt P. C., Campanero M. A., Troconiz I. F. - Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of émulsification versus digestibility. - Int. J. Pharm., 270, 109-118, 2004. (Pubitemid 38077092)
38. Nielsen F. S., Petersen K. B., Müllertz A. - Bioavailability of probucol from lipid and surfactant based formulations in minipigs: Influence of droplet size and dietary state. - Eur. J. Pharm. Biopharm., 69, 553-562, 2008.
39. O'Driscoll C. M., Griffin B. T. - Biopharmaceutical challenges associated with drugs with low aqueous solubility-The potential impact of lipid-based formulations. - Adv. Drug Delivery. Rev., 60, 617-624, 2008.
40. Fatouros D. G., Bergenstahl B., Müllertz A. - Morphological observations on a lipid-based drug delivery system during in vitro digestion. - Eur. J. Pharm. Sci., 31, 85-94, 2007. (Pubitemid 46660577)
41. Staggers J. E., Hernell O., Stafford R. J., Carey M. C. - Physicalchemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. - Biochemistry (Mosc.), 29, 2028-2040, 1990. (Pubitemid 20085428)
42. Hernell O., Staggers J. E., Carey M. C. - Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. - Biochemistry (Mosc.), 29, 2041-2056, 1990. (Pubitemid 20085429)
43. Kossena G. A., Charman W. N., Boyd B. J., Dunstan D. E., Porter C. J. H. - Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: A phase diagram approach. - J. Pharm. Sci., 92, 332-348, 2004. (Pubitemid 38174256)
44. Kossena G. A., Charman W. N., Boyd B. J., Porter C. J. H. - Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. - J. Pharm. Sci., 94, 481-492, 2005. (Pubitemid 40476514)
45. Thomas N., Müllertz A., Graf A., Rades T. - Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. - J. Pharm. Sci., 101, 1721-1731, 2012.
46. Williams H. D., Sassene P., Kleberg K., Bakala-N'Goma J.-C., Calderone M., Jannin V., Igonin A., Partheil A., Marchaud D., Jule E., Vertommen J., Maio M., Blundell R., Benameur H., Carrière F., Müllertz A., Porter C. J. H., Pouton C. W. - Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. - J. Pharm. Sci., 101, 3360-3380, 2012.
47. Strickley R. G. - Solubilizing excipients in oral and injectable formulations. - Pharm. Res., 21, 201-230, 2004. (Pubitemid 38221966)
48. Pouton C. W. - Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. - Eur. J. Pharm. Sci., 11, S93-S98, 2000.
49. Williams H. D., Trevaskis N. L., Charman S. A., Shanker R. M., Charman W. N., Pouton C. W., Porter C. J. H. - Strategies to address low drug solubility in discovery and development. - Pharmacol. Rev., 65, 315-499, 2013.
50. Amidon G., Lennernaes H., Shah V. P., Crison J. R. - Atheoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm. Res., 12, 413-420, 1995.
51. Aaltonen J., Alleso M., Mirza S., Koradia V., Gordon K. C., Rantanen J. - Solid form screening - A review. - Eur. J. Pharm. Biopharm., 71, 23-37, 2009.
52. Li P., Zhao L. - Developing early formulations: Practice and perspective. - Int. J. Pharm., 341, 1-19, 2007. (Pubitemid 47088122)
53. Khoo S.-M., Edwards G. A., Porter C. J. H., Charman W. N. - A conscious dog model for assessing the absorption, enterocytebased metabolism, and intestinal lymphatic transport of halofantrine. - J. Pharm. Sci., 90, 1599-1607, 2001. (Pubitemid 32979754)
54. Morozowich W., Gao P. - Improving the oral absorption of poorly soluble drugs using SEDDS and S-SEDDS formulations. - In: Yihong Q., Yisheng C., Zhang G. Z., Liu L., Porter W. R. (Eds.), Developing Solid Oral Dosage Forms, Academic Press, San Diego, 2009, p. 443-468.
55. Nielsen F. S., Gibault E., Ljusberg-WahrenH., Arleth L., Pedersen J. S., Müllertz A. - Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. - J. Pharm. Sci., 96, 876-892, 2007. (Pubitemid 46657875)
56. Nielsen P. B., Müllertz A., Norling T., Kristensen H. G. - The effect of [alpha]-tocopherol on the in vitro solubilisation of lipophilic drugs. - Int. J. Pharm., 222, 217-224, 2001. (Pubitemid 32568365)
57. Larsen A. T., Ogbonna A., Abu-Rhmaileh R., Abrahamsson B., Østergaard J., Müllertz A. - SNEDDS containing poorly water soluble cinnarizine; development and in vitro characterization of dispersion, digestion and solubilization. - Pharmaceutics, 4, 641-665, 2012.
58. Fatouros D. G., Karpf D. M., Nielsen F. S., Müllertz A. - Clinical studies with oral lipid based formulations of poorly soluble compounds. - Ther. Clin. Risk Manag., 3, 591-604, 2007. (Pubitemid 47496964)
59. Stillhart C., Kuentz M. - Comparison of high-resolution ultrasonic resonator technology and Raman spectroscopy as novel process analytical tools for drug quantification in self-emulsifying drug delivery systems. - J. Pharm. Biomed. Anal., 59, 29-37, 2012.
60. Mueller E. A., Kovarik J. M., van Bree J. B., Tetzloff W., Grevel J., Kutz K. - Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. - Pharm. Res., 11, 301-304, 1994. (Pubitemid 24076228)
61. Larsen A. T., Ohlsson A. G., Polentarutti B., Barker R. A., Phillips A. R., Abu-Rmaileh R., Dickinson P. A., Abrahamsson B., Østergaard J., Müllertz A. - Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation. - Eur. J. Pharm. Sci., 48, 339-350, 2013.
62. Mukherjee T., Plakogiannis F. M. - Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole. - J. Pharm. Pharmacol., 62, 1112-1120, 2010.
63. Sprunk A., Strachan C. J., Graf A. - Rational formulation development and in vitro assessment of SMEDDS for oral delivery of poorly water soluble drugs. - Eur. J. Pharm. Sci., 46, 508-515, 2012.
64. Ren S., Mu H., Alchaer F., Chtatou A., Müllertz A. - Optimization of self nanoemulsifying drug delivery system for poorly watersoluble drug using response surface methodology. - Drug Dev. Ind. Pharm., online first, doi: 10.3109/03639045.2012.710634, 1-8, 2012.
65. Larsen A. T., Sassene P., Müllertz A. - Invitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. - Int. J. Pharm., 417, 245-255, 2011.
66. Thomas N., Holm R., Rades T., Müllertz A. - Characterising lipid lipolysis and its implication in lipid-based formulation development. - AAPS J., 14, 860-871, 2012.
67. Sek L., Pouton C. W., Charman W. N. - Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. - J. Pharm. Biomed. Anal., 25, 651-661, 2001. (Pubitemid 32493922)
68. Parmentier J., Thomas N., Müllertz A., Fricker G., Rades T. - Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis. - Int. J. Pharm., 437, 253-263, 2012.
69. Fatouros D. G., Deen G. R., Arleth L., Bergenstahl B., Nielsen F. S., Pedersen J. S., Müllertz A. - Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. - Pharm. Res., 24, 1844-1853, 2007. (Pubitemid 47389238)
70. Warren D. B., Anby M. U., Hawley A., Boyd B. J. - Real time evolution of liquid crystalline nanostructure during the digestion of formulation lipids using synchrotron small-angle X-ray scattering. - Langmuir, 27, 9528-9534, 2011.
71. Zangenberg N. H., Müllertz A., Kristensen H. G., Hovgaard L. - A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. - Eur. J. Pharm. Sci., 14, 115-122, 2001. (Pubitemid 32737533)
72. Zangenberg N. H., Müllertz A., Kristensen H. G., Hovgaard L. - A dynamic in vitro lipolysis model. II. Evaluation of the model. - Eur. J. Pharm. Sci., 14, 237-244, 2001. (Pubitemid 32884320)
73. Porter C. J. H., Kaukonen A. M., Boyd B. J., Edwards G. A., Charman W. N. - Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. - Pharm. Res., 21, 1405-1412, 2004. (Pubitemid 39149655)
74. Pouton C. W. - Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. - Eur. J. Pharm. Sci., 29, 278-287, 2006. (Pubitemid 44740131)
75. Gao P., Akrami A., Alvarez F., Hu J., Li L., Ma C., Surapaneni S. - Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. - J. Pharm. Sci., 98, 516-528, 2009.
76. Thomas N., Holm R., Garmer M., Karlsson J. J., Müllertz A., Rades T. - Supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. - AAPS J., 15, 219-227, 2013.
77. Thomas N., Holm R., Müllertz A., Rades T. - In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). - J. Controlled Release, 160, 25-32, 2012.
78. Sassene P. J., Knopp M. M., Hesselkilde J. Z., Koradia V., Larsen A., Rades T., Müllertz A. - Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate. - J. Pharm. Sci., 99, 4982-4991, 2010.
79. Sha X., Yan G., Wu Y., Li J., Fang X. - Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. - Eur. J. Pharm. Sci., 24, 477-486, 2005. (Pubitemid 40387261)
80. Hilgendorf C., Spahn-Langguth H., Regärdh C. G., Lipka E., Amidon G. L., Langguth P. - Caco-2 versus caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. - J. Pharm. Sci., 89, 63-75, 2000. (Pubitemid 30080155)
81. Mahler G. J., Shuler M. L., Glahn R. P. - Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. - J. Nutr. Biochem., 20, 494-502, 2009.
82. Walter E., Janich S., Roessler B. J., Hilfinger J. M., Amidon G. L. - HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans. - J. Pharm. Sci., 85, 1070-1076, 1996. (Pubitemid 26338920)
83. Kararli T. T. - Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. - Biopharm. Drug Dispos., 16, 351-380, 1995.
84. Han S. F., Yao T. T., Zhang X. X., Gan L., Zhu C., Yu H.-z., Gan Y. - Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. - Int. J. Pharm., 379, 18-24, 2009.
85. Holm R., Jorgensen E. B., Harborg M., Larsen R., Holm P., Müllertz A., Jacobsen J. - A novel excipient, 1-perf luorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. - Eur. J. Pharm. Sci., 42, 416-422, 2011.
86. Hong J.-Y., Kim J.-K., Song Y.-K., Park J.-S., Kim C.-K. - A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. - J. Controlled Release, 110, 332-338, 2006. (Pubitemid 41827486)
87. Holm R., Porter C. J. H., Edwards G. A., Müllertz A., Kristensen H. G., Charman W. N. - Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. - Eur. J. Pharm. Sci., 20, 91-97, 2003. (Pubitemid 37103236)
88. Kang B. K., Lee J. S., Chon S. K., Jeong S. Y., Yuk S. H., Khang G., Lee H. B., Cho S. H. - Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. - Int. J. Pharm., 274, 65-73, 2004. (Pubitemid 38457007)
89. Grove M., Pedersen G. P., Nielsen J. L., Müllertz A. - Bioavailability of seocalcitol. (III) Administration of lipid-based formulations to minipigs in the fasted and fed state. - Eur. J. Pharm. Sci., 31, 8-15, 2007. (Pubitemid 46601865)
90. Bode G., Clausing P., Gervais F., Loegsted J., Luft J., Nogues V., Sims J. - The utility of the minipig as an animal model in regulatory toxicology. - J. Pharmacol. Toxicol. Methods, 62, 196-220, 2010.
91. Lentz K. - Current methods for predicting human food effect. - AAPS J., 10, 282-288, 2008.
92. Grove M., Pedersen G. P., Nielsen J. L., Müllertz A. - Bioavailability of seocalcitol. (I) Relating solubility in biorelevant media with oral bioavailability in rats - effect of medium and long chain triglycerides. - J. Pharm. Sci., 94, 1830-1838, 2005. (Pubitemid 41360876)
93. Akimoto M., Nagahata N., Furuya A., Fukushima K., Higuchi S., Suwa T. - Gastric pH profiles of beagle dogs and their use as an alternative to human testing. - Eur. J. Pharm. Biopharm., 49, 99-102, 2000. (Pubitemid 30126056)
94. Cuine J. F., Claire L., McEvoy C. L., Charman W. N., Pouton C. W., Edwards G. A., Benameur H., Porter C. J. H. - Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. - J. Pharm. Sci., 97, 995-1012, 2008. (Pubitemid 351293898)